Medication development in opioid addiction: Meaningful clinical end points.

Nora D Volkow Janet WoodcockWilson M ComptonDouglas C ThrockmortonPhil SkolnickSharon HertzEric M Wargo

Published in: Science translational medicine (2019)

The FDA's "abstinence" outcome measure for approval of new medications to treat opioid-use disorders has been difficult to achieve; developing and validating alternative meaningful outcomes could facilitate drug development.

Keyphrases

chronic pain
pain management
healthcare
smoking cessation
adverse drug
type diabetes
drug administration
adipose tissue